Berry Genomics Co. Ltd. Class A

As of June 30, 2026, Berry Genomics Co. Ltd. Class A carries a market capitalization of 2.64B, placing it among publicly traded companies globally. Its enterprise value stands at 2.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Berry Genomics Co. Ltd. Class A has 353.52M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Berry Genomics Co. Ltd. Class A maintains a current ratio of 2.12, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Berry Genomics Co. Ltd. Class A recorded 6.54M in income tax expense.

As of the close on October 23, 2026, Berry Genomics Co. Ltd. Class A's stock has declined approximately 23.47% over the past 52 weeks. The 50-day moving average sits at 9.59, while the 200-day moving average is 10.06.

As of June 30, 2026, Berry Genomics Co. Ltd. Class A holds 238.60M in cash and equivalents against 228.97M in total debt, resulting in a net debt position of -117.13M. Total book value stands at 1.42B, with working capital of 598.36M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Berry Genomics Co. Ltd. Class A paid dividends of 0.01 per share.

Berry Genomics Co. Ltd. Class A's most recent stock split took place on May 25, 2001 with a 5:7 split ratio.